N-Methanocarbathymidine

Drug Profile

N-Methanocarbathymidine

Alternative Names: N-MCT

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator N&N Pharmaceuticals
  • Class
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Herpes simplex virus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase I Herpes zoster
  • Preclinical Herpes simplex virus infections; Poxvirus infections

Most Recent Events

  • 27 Sep 2016 N-Methanocarbathymidine receives Orphan Drug status for Herpes simplex virus infections (In neonates) in USA
  • 20 Apr 2016 Phase-I clinical trials in Herpes zoster (In volunteers) in USA (PO)
  • 01 Apr 2016 Preclinical trials in Herpes simplex virus infections in USA (PO) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top